Composition for prevention or treatment of allergic skin disease containing GPCR19 agonist as active ingredient {Composition for preventing or allergic dermatitis compounding GPCR 19 agonistasactive ingredient}
The present invention relates to a GPCR19 agonist, or a pharmaceutical composition for preventing or treating allergic skin disease containing sodium taurodeoxycholate and a derivative thereof as an active ingredient, an oral agent, an injection, and an allergic skin disease As a preventive and ameliorating topical preparation and cosmetic composition, it exhibits superior effects in the treatment and improvement of allergic dermatitis compared to existing steroid ointments and immunosuppressive ointments, and is a demand factor for allergic dermatitis. Reduces the amount of certain serum immunoglobulin IgE directly, increases TH1 cytokines that alleviate allergic dermatitis disease, decreases TH2 cytokines that exacerbate allergic dermatitis disease, reduces mast cells within dermal cells As a pharmaceutical composition for the prevention and treatment of allergic skin diseases to reduce infiltration of eosinophils and neutrophils You can use.本発明は、GPCR19作用剤、又はタウロデオキシコール酸ナトリウム(Sodium taurodeoxycholate)及びその誘導体を有効成分として含有するアレルギー性皮膚疾患予防又は治療用医薬組成物、経口剤、注射剤、及びアレルギー性皮膚疾患予防及び改善用外用剤及び化粧料組成物に関し、既存のステロイド軟膏及び免疫抑制剤軟膏と比べてもアレルギー性皮膚炎の治療及び改善に優秀な効果を表し、アレルギー性皮膚炎病症の需要因子である血清免疫グロブリンIgEの量を直接的に減少させ、アレルギー性皮膚炎の病症を緩和させるTH1サイトカインは増加させ、アレルギー性皮膚炎の病症を悪化させるTH2サイトカインは減少させ、真皮細胞内に肥満細胞、好酸球及び好中球の浸潤を減少させるため、アレルギー性皮膚疾患予防及び治療用の医薬品組成物として活用できる。
